Scarica l'app Stockscreener
19.87
3.92%
0.75
Dopo l'orario di chiusura:
19.90
0.03
+0.15%
Precedente Chiudi:
$19.12
Aprire:
$19.12
Volume 24 ore:
161.68K
Relative Volume:
0.80
Capitalizzazione di mercato:
$307.78M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+13.41%
1M Prestazione:
-0.70%
6M Prestazione:
-12.54%
1 anno Prestazione:
+31.76%
Intervallo 1D:
$18.76
$20.01
Intervallo di 1 settimana:
$17.49
$20.01
Portata 52W:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Confronta NGNE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
19.87 | 296.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Craig Hallum | Buy |
| 2025-05-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2024-03-21 | Iniziato | William Blair | Outperform |
| 2024-01-08 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-05 | Iniziato | Stifel | Buy |
| 2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
Neurogene (NASDAQ:NGNE) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Neurogene (NGNE) with Outperform Recommendation - Nasdaq
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Aug Macro: Is Neurogene Inc stock risky to hold nowQuarterly Portfolio Report & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Risk Analysis: Can Neurogene Inc outperform under higher oil pricesTrade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, advancing toward commercialization - TradingView
Neurogene (NASDAQ:NGNE) Given “Buy” Rating at HC Wainwright - Defense World
Market Fear: Whats the analyst consensus on Neurogene Inc2025 Market Trends & Daily Volume Surge Signals - baoquankhu1.vn
Short Covering: Whats the analyst consensus on Neurogene IncJuly 2025 WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
HC Wainwright & Co. Reiterates Buy Rating for NGNE with $70 Pric - GuruFocus
Neurogene doses multiple patients in Rett syndrome gene therapy trial By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Neurogene Inc. Reports Q3 2025 Financial Results - MSN
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin - Investing.com Nigeria
Market Review: Whats the analyst consensus on Neurogene IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Neurogene doses multiple patients in Rett syndrome gene therapy trial - Investing.com
Neurogene outlines 2026 milestones for NGN-401 Rett therapy - TipRanks
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - marketscreener.com
Neurogene Inc Announces Key Milestones for NGN-401 Gene Therapy - TradingView — Track All Markets
Boston Herald - FinancialContent
Neurogene Announces Positive Interim Data for NGN-401 - MSN
User | custercountychief.comNeurogene Inc.Common Stock (Nasdaq:NGNE) Stock Quote - FinancialContent
Is Neurogene Inc. stock a good choice for value investors2025 Volatility Report & Safe Capital Allocation Plans - Улправда
Is Neurogene Inc. stock gaining market shareJuly 2025 Macro Moves & Consistent Return Investment Signals - Улправда
What insider purchases suggest about Neurogene Inc. (UU8) stockJuly 2025 Retail & Safe Entry Point Identification - ulpravda.ru
Neurogene Inc. (NGNE) Stock Analysis: Uncovering a 208% Potential Upside in Biotechnology - DirectorsTalk Interviews
Will Neurogene Inc. (UU8) stock attract long term capital inflows2025 Winners & Losers & Community Verified Trade Alerts - Улправда
How Neurogene Inc. (UU8) stock correlates with oil marketsAI-Driven Market Analysis & Free Realize Exceptional Returns - Улправда
Will Neurogene Inc. stock benefit from upcoming earnings reportsStock Price Forecasts & Minimal Investment Big Returns - ulpravda.ru
What analysts say about Neurogene Inc UU8 stockStock Liquidity Analysis & Free Stock Predictions and Analysis - Early Times
Shanti Educational Initiatives Limited (539921) Announces Strategic ShiftEarly Times Newspaper Jammu - Early Times
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - New Castle News
Genetic medicines firm Neurogene opens its health conference talk online - Stock Titan
Neurogene Inc.Common Stock (NQ: NGNE - FinancialContent
Pullback Watch: Is Neurogene Inc stock a good choice for value investorsJuly 2025 Retail & AI Enhanced Trading Signals - moha.gov.vn
Breakout Move: How Applied Industrial Technologies Inc AT4 stock reacts to monetary easingTrend Reversal & Safe Swing Trade Setup Alerts - moha.gov.vn
Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation - Sahm
Craig-Hallum Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - MSN
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
What catalysts could drive Neurogene Inc. stock higherPortfolio Diversification Tips & Free Hedging Tactics for Volatile Markets - bollywoodhelpline.com
Sell Signal: Is Neurogene Inc stock gaining market shareJuly 2025 Sentiment & Low Risk High Reward Ideas - moha.gov.vn
Earnings Beat: Is Neurogene Inc stock a good choice for value investorsQuarterly Portfolio Summary & Verified Entry Point Signals - moha.gov.vn
Why Neurogene Inc. stock appeals to dividend seekersQuarterly Profit Summary & Weekly Breakout Watchlists - Улправда
Will Neurogene Inc. stock gain from lower inflationWeekly Trade Report & Daily Price Action Insights - DonanımHaber
Can Neurogene Inc. stock continue upward trend2025 Key Highlights & Expert Verified Movement Alerts - DonanımHaber
Will Neurogene Inc. stock split again soonJuly 2025 Retail & Real-Time Volume Analysis Alerts - Улправда
Will Neurogene Inc. (UU8) stock benefit from Fed rate cutsRecession Risk & AI Powered Market Entry Ideas - DonanımHaber
Momentum Shift: Why Neurogene Inc. stock appeals to dividend seekersWeekly Trade Summary & Weekly High Return Opportunities - Улправда
Neurogene Inc Azioni (NGNE) Dati Finanziari
Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):